Biotechnology in Diagnosis and Treatment: An Introduction to Biotechnology and Its Impact on Modern Medicine

1. Introduction

Biotechnology is broadly defined as the use of biological systems, living organisms, or their derivatives to develop products and technologies that benefit human health, agriculture, and industry.[1] While the term encompasses a wide range of fields, its most transformative applications have occurred in medicine, where it has redefined how diseases are understood, detected, and treated at the molecular level.

The history of medical biotechnology can be traced to the 1970s, when recombinant DNA technology allowed scientists to insert foreign genes into bacteria to produce human proteins such as insulin.[2] Since then, the field has expanded dramatically. The sequencing of the human genome in 2003 opened a new era of genomic medicine.[3] The development of high-throughput sequencing, CRISPR-Cas9 gene editing, and advanced immunotherapies have continued to accelerate progress at a pace previously unimaginable.

Today, biotechnology underpins the majority of new drug approvals. According to the Biotechnology Innovation Organization, more than 70% of drugs currently in clinical development use biotechnology platforms.[4] Understanding this field is essential for students of medicine, biology, and public health alike.

2. Biotechnology in Medical Diagnosis

One of the most consequential contributions of biotechnology has been in diagnostics — the ability to detect disease earlier, more accurately, and less invasively than traditional clinical methods. The following sections describe the major biotechnology-based diagnostic platforms in clinical use today.

2.1 Polymerase Chain Reaction (PCR)

PCR, developed by Kary Mullis in 1983 (Nobel Prize in Chemistry, 1993), is a technique that amplifies specific segments of DNA or RNA to detectable levels from very small samples.[6] In clinical diagnostics, PCR is used to detect pathogens including viruses (HIV, SARS-CoV-2, influenza), bacteria (M. tuberculosis), and genetic mutations associated with hereditary cancers. Real-time quantitative PCR (qPCR) additionally allows quantification of viral load — critical for monitoring treatment response in HIV/AIDS and chronic hepatitis.[7]

2.2 Next-Generation Sequencing (NGS)

Next-generation sequencing platforms allow the rapid sequencing of millions of DNA fragments simultaneously, enabling whole-genome, whole-exome, or targeted panel sequencing at a fraction of the cost of the original Human Genome Project.[8] NGS has transformed the diagnosis of rare genetic disorders, oncology (tumor mutational profiling), and infectious disease surveillance. A landmark study in the New England Journal of Medicine found that NGS-based testing identified actionable mutations in nearly 25% of pediatric cancer patients who had exhausted standard diagnostic workups.[9]

2.3 Immunoassays and Biomarker Detection

Enzyme-linked immunosorbent assay (ELISA) and related immunoassay technologies exploit the high specificity of antibody-antigen binding to detect proteins, hormones, or small molecules in biological fluids.[10] Serum biomarkers such as prostate-specific antigen (PSA) for prostate cancer, troponin for myocardial infarction, and CA-125 for ovarian cancer monitoring are routinely measured via immunoassay platforms in clinical laboratories worldwide.

2.4 Liquid Biopsy

Liquid biopsy refers to the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or exosomes in blood plasma.[11] This non-invasive approach enables early cancer detection, real-time monitoring of treatment response, and identification of resistance mutations without repeated tissue sampling. Several liquid biopsy tests have received FDA clearance, including Guardant360 and FoundationOne Liquid CDx for solid tumors.[12]

2.5 Genetic Screening and Carrier Testing

Preconception and prenatal genetic screening allows identification of carriers for conditions including cystic fibrosis, sickle cell disease, Tay-Sachs disease, and fragile X syndrome.[13] Cell-free fetal DNA (cfDNA) testing — marketed as non-invasive prenatal testing (NIPT) — detects chromosomal aneuploidies such as Down syndrome (trisomy 21) with sensitivity exceeding 99%.[14]

Table 1. Summary of Key Biotechnology-Based Diagnostic Tools

Technology	Principle	Clinical Applications	Notable Example
PCR / qPCR	DNA amplification	Infectious disease, oncology	COVID-19 testing
Next-Gen Sequencing	High-throughput DNA sequencing	Rare disease, cancer genomics	Tumor profiling
ELISA / Immunoassay	Antibody-antigen binding	Hormone levels, cancer markers	HIV antibody test
Liquid Biopsy	ctDNA / CTC analysis	Early cancer detection, monitoring	Guardant360
cfDNA / NIPT	Free fetal DNA sequencing	Prenatal chromosomal screening	Down syndrome detection

3. Biotechnology in Medical Treatment

The impact of biotechnology on therapeutics has been equally transformative. Biological therapies — large, complex molecules produced using living cells — now represent the fastest-growing segment of the global pharmaceutical market.[4]

3.1 Recombinant Proteins and Biologics

The first major therapeutic product of recombinant DNA technology was human insulin, approved by the FDA in 1982.[2] Prior to this, insulin was derived from pig or cow pancreatic tissue, carrying risks of immunogenic reactions. Today, recombinant protein therapeutics include erythropoietin (for anemia in chronic kidney disease), human growth hormone, clotting factors for hemophilia, and granulocyte colony-stimulating factors used in oncology supportive care.[15]

3.2 Monoclonal Antibodies

Monoclonal antibodies (mAbs) are laboratory-produced proteins designed to target specific antigens. Since the approval of the first therapeutic mAb in 1986, more than 100 have been approved by the FDA.[16] In oncology, trastuzumab (Herceptin®) targets HER2-positive breast cancer,[17] while pembrolizumab (Keytruda®) is a PD-1 checkpoint inhibitor with approvals spanning multiple cancer types. In autoimmune disease, adalimumab (Humira®) — a TNF-α inhibitor — is among the world's best-selling drugs, used in rheumatoid arthritis, Crohn's disease, and psoriasis.[18]

3.3 mRNA Vaccines

mRNA vaccine technology instructs host cells to transiently produce a target antigen (such as a viral spike protein), eliciting an immune response without live or attenuated pathogens.[19] The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines demonstrated 90–95% efficacy against symptomatic disease in pivotal Phase III trials.[20] mRNA platforms are now in clinical trials for cancer vaccines, HIV, influenza, and rare genetic diseases — representing a fundamental shift in vaccine development.[21]

3.4 Gene Therapy

Gene therapy involves the introduction, alteration, or replacement of genetic material within a patient's cells to treat or cure disease.[22] Improved viral vector designs have enabled landmark approvals: onasemnogene abeparvovec (Zolgensma®) for spinal muscular atrophy type 1 — a single AAV9 gene therapy showing dramatic clinical improvements[24] — and voretigene neparvovec (Luxturna®), which restores functional vision in patients with inherited retinal dystrophy.[25]

3.5 CRISPR-Cas9 Gene Editing

CRISPR-Cas9 is a precision gene-editing tool adapted from a bacterial immune defense mechanism, for which Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry in 2020.[26] In December 2023, the FDA approved exagamglogene autotemcel (Casgevy®) — the first CRISPR-based therapeutic — for sickle cell disease and transfusion-dependent beta-thalassemia.[27]

3.6 CAR-T Cell Therapy

Chimeric antigen receptor T-cell (CAR-T) therapy involves genetically engineering a patient's own T lymphocytes ex vivo to express a synthetic receptor targeting a tumor antigen, then infusing the modified cells back into the patient.[28] The FDA approved tisagenlecleucel (Kymriah®) in 2017 for relapsed/refractory B-cell acute lymphoblastic leukemia in pediatric patients, achieving complete remission rates of 81% in a pivotal trial.[29]

4. Societal and Healthcare Impact

The cumulative impact of biotechnology on global health has been profound. Life expectancy in high-income countries has increased from approximately 68 years in 1960 to over 79 years in 2023, driven in substantial part by advances in treating infectious diseases, cardiovascular disease, and cancer.[30] HIV/AIDS mortality has declined by more than 64% since its peak in the mid-1990s, largely due to antiretroviral drugs developed using molecular biology techniques.[31]

The global biotechnology market was valued at approximately $1.55 trillion in 2024 and is projected to grow at a CAGR of nearly 14% through 2030, driven by biologics, cell and gene therapy, and diagnostics.[32] However, high development and manufacturing costs mean that many breakthrough therapies carry list prices exceeding $1 million per treatment course, raising urgent questions about healthcare equity and access in low- and middle-income countries.[33]

5. Future Directions

The next decade promises further expansion of biotechnology's medical frontier. Personalized medicine — tailoring treatment to an individual's unique genetic, proteomic, and microbiome profile — is advancing rapidly with improved bioinformatics infrastructure and reduced sequencing costs.[34]

Artificial intelligence and machine learning are accelerating drug discovery, with platforms such as AlphaFold revolutionizing protein structure prediction and enabling novel target identification.[35] In 2023, the first AI-designed antibiotic effective against drug-resistant Acinetobacter baumannii was reported in Nature.[36]

Organoids — miniaturized three-dimensional tissue models derived from stem cells — are emerging as powerful platforms for disease modeling and drug testing.[37] Three-dimensional bioprinting of vascularized tissue constructs moves closer to the long-term goal of transplantable organs produced from a patient's own cells.[38] Synthetic biology additionally offers the potential to engineer microorganisms that serve as living therapeutics, biosensors, or programmable drug delivery vehicles.[39]